These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 31335590

  • 1. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
    Haaland RE, Martin A, Livermont T, Fountain J, Dinh C, Holder A, Lupo LD, Hall L, Conway-Washington C, Kelley CF.
    J Acquir Immune Defic Syndr; 2019 Nov 01; 82(3):252-256. PubMed ID: 31335590
    [Abstract] [Full Text] [Related]

  • 2. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.
    AIDS; 2011 Mar 27; 25(6):F7-12. PubMed ID: 21412057
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K, Szwarcberg J, White K, Cheng AK, Kearney BP, GS-236-0103 Study Team.
    Lancet; 2012 Jun 30; 379(9835):2429-2438. PubMed ID: 22748590
    [Abstract] [Full Text] [Related]

  • 5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
    Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK, GS-US-236-0102 study team.
    Lancet; 2012 Jun 30; 379(9835):2439-2448. PubMed ID: 22748591
    [Abstract] [Full Text] [Related]

  • 6. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á.
    Basic Clin Pharmacol Toxicol; 2019 Apr 30; 124(4):479-490. PubMed ID: 30388308
    [Abstract] [Full Text] [Related]

  • 7. EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
    Andrade A, Fuchs EJ, Marzinke MA, Abdul Massih S, Breakey J, Beselman S, McNicholl I, Hendrix CW.
    AIDS Res Hum Retroviruses; 2023 Jan 30; 39(1):38-43. PubMed ID: 36301928
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S, Custodio JM, Wei X, Wang H, Fordyce M, Dave A, Ling KH, Szwarcberg J, Kearney BP.
    J Acquir Immune Defic Syndr; 2016 Jul 01; 72(3):281-8. PubMed ID: 26885802
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial.
    Zhang F, Wu H, Cai W, Ma P, Zhao Q, Wei H, Lu H, Wang H, He S, Chen Z, Chen Y, Wang M, Wan W, Fu H, Qin H.
    Lancet Reg Health West Pac; 2024 Aug 01; 49():101143. PubMed ID: 39092318
    [Abstract] [Full Text] [Related]

  • 13. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M, Badowski ME, Chiampas T, Young J, Patel M, Vaughn P.
    Int J STD AIDS; 2017 Jul 01; 28(8):766-772. PubMed ID: 27587601
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
    Schrijvers R, Debyser Z.
    Expert Opin Pharmacother; 2012 Sep 01; 13(13):1969-83. PubMed ID: 22849516
    [Abstract] [Full Text] [Related]

  • 16. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
    Imaz A, Niubó J, Cottrell ML, Perez E, Kashuba ADM, Tiraboschi JM, Morenilla S, Garcia B, Podzamczer D.
    Clin Infect Dis; 2019 Sep 27; 69(8):1403-1409. PubMed ID: 30561517
    [Abstract] [Full Text] [Related]

  • 17. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, Brinson C, Kulkarni R, Garner W, Ebrahimi R, Cao H, Cheng A, Szwarcberg J.
    HIV Clin Trials; 2014 Sep 27; 15(2):51-6. PubMed ID: 24710918
    [Abstract] [Full Text] [Related]

  • 18. Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
    Devred I, Kayembe K, Valin N, Rougier H, Shinga BW, Lambert-Niclot S, Chiarabini T, Meyohas MC, Lacombe K.
    BMC Infect Dis; 2023 Sep 04; 23(1):578. PubMed ID: 37667182
    [Abstract] [Full Text] [Related]

  • 19. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.
    Antivir Ther; 2015 Sep 04; 20(3):317-27. PubMed ID: 25321623
    [Abstract] [Full Text] [Related]

  • 20. Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
    Kulkarni R, Hodder SL, Cao H, Chang S, Miller MD, White KL.
    HIV Clin Trials; 2017 Jul 04; 18(4):164-173. PubMed ID: 28891788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.